Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation

Thromb Haemost. 2002 Feb;87(2):199-205.

Abstract

Compared to second generation, the use of third generation oral contraceptives has been associated with an increased risk of venous thrombosis especially in women with the factor V Leiden mutation. To find an explanation for these risk differences we investigated the effects of desogestrel- and levonorgestrel-containing oral contraceptives as well as their progestagens separately on the coagulation system in the absence or presence of the factor V Leiden mutation. In a single center, double blind trial, 51 women without and 35 women with the factor V Leiden mutation were randomized to either a second generation (30 microg ethinylestradiol/150 microg levonorgestrel) or a third generation (30 microg ethinylestradiol/150 microg desogestrel) oral contraceptive. After two cycles of use and a wash-out period of 2 menstrual cycles, the participants received the corresponding progestagen-only preparation containing 150 microg levonorgestrel or 150 microg desogestrel. In plasmas of the participating women fragment 1+2, factor V, VII, VIII, IX, X and XI were determined. Both combined oral contraceptives induced a decrease in factor V, whereas the levels of all other coagulant parameters increased. However, in women without the factor V Leiden mutation the effects of desogestrel-containing preparations were significantly different compared to levonorgestrel-containing oral contraceptives for factor V (-8.0; 95% CI -13.4 to -2.6), factor VII (26.8; 95% CI 15.5 to 38.0) and factor IX (-9.6; 95% CI -16.2 to -3.2). When these women used progestagen-only pills, a differential effect between desogestrel and levonorgestrel was only found for factor IX (-6.5; 95% CI -11.4 to -1.5). In carriers of the factor V Leiden mutation desogestrel-containing oral contraceptives induced more pronounced changes in factor V (-14.2; 95% CI -22.4 to -6.0) and factor VII (36.1; 95% CI 19.7 to 52.6) compared to levonorgestrel-containing oral contraceptives. Comparing desogestrel- and levonorgestrel-only, only for factor V a differential effect was found in these women (-9.5; 95% CI -18.3 to -0.6). It appears that desogestrel-containing oral contraceptives have a more pronounced effect on the coagulation system than levonorgestrel-containing oral contraceptives which may be explained by a less effective compensation of the thrombotic effect of ethinylestradiol by desogestrel.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activated Protein C Resistance / blood
  • Activated Protein C Resistance / genetics*
  • Adult
  • Blood Coagulation / drug effects*
  • Blood Coagulation Factors / analysis*
  • Contraceptives, Oral, Combined / adverse effects*
  • Contraceptives, Oral, Combined / pharmacology
  • Contraceptives, Oral, Hormonal / adverse effects*
  • Contraceptives, Oral, Hormonal / pharmacology
  • Desogestrel / administration & dosage
  • Desogestrel / adverse effects*
  • Desogestrel / pharmacology
  • Double-Blind Method
  • Ethinyl Estradiol / administration & dosage
  • Ethinyl Estradiol / adverse effects*
  • Ethinyl Estradiol / pharmacology
  • Factor IX / analysis
  • Factor V / analysis
  • Factor V / genetics*
  • Factor VII / analysis
  • Female
  • Humans
  • Levonorgestrel / administration & dosage
  • Levonorgestrel / adverse effects*
  • Levonorgestrel / pharmacology
  • Peptide Fragments / analysis
  • Prothrombin / analysis
  • Thrombophilia / blood
  • Thrombophilia / chemically induced*
  • Thrombophilia / genetics

Substances

  • Blood Coagulation Factors
  • Contraceptives, Oral, Combined
  • Contraceptives, Oral, Hormonal
  • Peptide Fragments
  • factor V Leiden
  • prothrombin fragment 1.2
  • Ethinyl Estradiol
  • Levonorgestrel
  • Desogestrel
  • Factor V
  • Factor VII
  • Prothrombin
  • Factor IX